Biotie Therapies - Company Announcement

BIOTIE ANNOUNCES THAT THE DELISTING OF ITS ADS HAS BECOME EFFECTIVE

BIOTIE THERAPIES CORP.         STOCK  EXCHANGE  RELEASE    13 June 2016, at
4.30 p.m. (EET)

BIOTIE THERAPIES CORP. ANNOUNCES THAT THE DELISTING OF ITS AMERICAN DEPOSITARY
SHARES FROM NASDAQ GLOBAL SELECT MARKET HAS BECOME EFFECTIVE

Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) ("Biotie" or the "Company")
announces that the voluntary delisting of its American Depositary Shares
("ADSs") from the NASDAQ Global Select Market ("Nasdaq US") became effective
prior to the opening of trading on 13 June, 2016, following the filing, on 2
June 2016, of an application on Form 25 with the U.S. Securities and Exchange
Commission (the "SEC") for notifying the SEC of the delisting of the Company's
ADSs from NASDAQ US, as announced on 18 May 2016.

The delisting becoming effective means that the ADSs are no longer tradable on
any regulated security exchange. Biotie shares ("Shares") will remain listed on
Nasdaq Helsinki Ltd., although the Company intends to delist the Shares from
Nasdaq Helsinki Ltd. as soon as permitted and practicable under applicable laws.

Further details on Biotie's reporting obligations under applicable U.S
securities laws after the delisting of the ADSs becoming effective and the
treatment of the ADSs in the compulsory redemption proceedings initiated by
Acorda Therapeutics, Inc. ("Acorda") for Biotie's minority shares under the
Finnish Companies Act have been described in the stock exchange release issued
by Biotie on 18 May 2016.

Turku, 13 June 2016

Biotie Therapies Corp.
Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd.
Main Media

INFORMATION REGARDING BIOTIE

Biotie is a biopharmaceutical company focused on products for neurodegenerative
and psychiatric disorders. Biotie's development has delivered Selincro
(nalmefene) for alcohol dependence, which received European marketing
authorization in 2013 and is currently being rolled out across Europe by partner
H. Lundbeck A/S. The current development products include tozadenant for
Parkinson's disease, which is in Phase 3 development, and two additional
compounds which are in Phase 2 development for cognitive disorders including
Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare
fibrotic disease of the liver.

For more information, please visit www.biotie.com.

INFORMATION REGARDING ACORDA

Founded in 1995, Acorda is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with
neurological disorders, with its common stock listed on Nasdaq US.

Acorda has an industry leading pipeline of novel neurological therapies
addressing a range of disorders, including Parkinson's disease, epilepsy, post-
stroke walking deficits, migraine, and multiple sclerosis. Acorda markets three
FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release
Tablets, 10 mg.

For more information, please visit www.acorda.com.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Some of the statements contained in this announcement are forward-looking
statements, including Biotie's deregistration from U.S. reporting obligations,
which involve a number of risks and uncertainties. These statements are based on
current expectations, assumptions, estimates and projections, and involve known
and unknown risks, uncertainties and other factors that may cause results,
levels of activity, performance or achievements to be materially different from
any future statements. These statements are generally identified by words or
phrases such as "believe", "anticipate", "expect", "intend", "plan", "will",
"may", "should", "estimate", "predict", "potential", "continue" or the negative
of such terms or other similar expressions. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results and the
timing of events may differ materially from the expected results and/or timing
discussed in the forward-looking statements, and you should not place undue
reliance on these statements. Acorda and Biotie disclaim any intent or
obligation to update any forward-looking statements as a result of developments
occurring after the period covered by this announcement or otherwise.


[HUG#2020140]